Paper301783
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.
Von Hoff DD and 3 others. Cancer Treat Rep, 1977. Cited by 152 papers, by iCite.
Cite this record
ConductScience Library. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Papers, record 301783. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/301783
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leucovorin | Major topic |
| Methotrexate | Major topic |
| Neoplasms | Major topic |
| Drug Therapy, Combination | |
| Humans | |
| United States |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42122187 | Long-Term Kidney Outcomes in Paediatric Osteosarcoma Survivors: A 20-Year Multi-Centre Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122187 | PubMed |
| 38186937 | A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK. | Health Sci Rep | 2024 | https://conductscience.org/library/papers/38186937 | PubMed |
| 35236714 | Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. | Clin J Am Soc Nephrol | 2022 | https://conductscience.org/library/papers/35236714 | PubMed |
| 35147457 | Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. | J Oncol Pharm Pract | 2023 | https://conductscience.org/library/papers/35147457 | PubMed |
| 30853983 | Simultaneous Quantification of Methotrexate and Its Metabolite 7-Hydroxy-Methotrexate in Human Plasma for Therapeutic Drug Monitoring. | Int J Anal Chem | 2019 | https://conductscience.org/library/papers/30853983 | PubMed |
| 30799942 | Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study. | Clinicoecon Outcomes Res | 2019 | https://conductscience.org/library/papers/30799942 | PubMed |
| 28856465 | Guidelines for treatment of renal injury during cancer chemotherapy 2016. | Clin Exp Nephrol | 2018 | https://conductscience.org/library/papers/28856465 | PubMed |
| 24132809 | Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. | Pharmacotherapy | 2014 | https://conductscience.org/library/papers/24132809 | PubMed |
| 23760811 | Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. | Cancer Chemother Pharmacol | 2013 | https://conductscience.org/library/papers/23760811 | PubMed |
| 22652833 | Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. | J Cancer Res Clin Oncol | 2012 | https://conductscience.org/library/papers/22652833 | PubMed |
| 22432089 | High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. | Am J Blood Res | 2012 | https://conductscience.org/library/papers/22432089 | PubMed |
| 21301589 | Cancer chemotherapy: targeting folic acid synthesis. | Cancer Manag Res | 2010 | https://conductscience.org/library/papers/21301589 | PubMed |
| 11192475 | Clinical and preclinical pharmacokinetics of raltitrexed. | Clin Pharmacokinet | 2000 | https://conductscience.org/library/papers/11192475 | PubMed |
| 8599863 | High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model. | Cancer Chemother Pharmacol | 1996 | https://conductscience.org/library/papers/8599863 | PubMed |
| 8194163 | Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8194163 | PubMed |
| 7735697 | Interaction between methotrexate and indomethacin on a human normal haemopoietic cell line. | Br J Pharmacol | 1995 | https://conductscience.org/library/papers/7735697 | PubMed |
| 7726679 | Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. | Ann Surg | 1995 | https://conductscience.org/library/papers/7726679 | PubMed |
| 7250179 | Effect of urine pH and flow on renal clearance of methotrexate. | Eur J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7250179 | PubMed |
| 6994913 | The practical benefits of pharmacokinetics in the use of antineoplastic agents. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/6994913 | PubMed |
| 6781586 | Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation. | Br Med J (Clin Res Ed) | 1981 | https://conductscience.org/library/papers/6781586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/301783
GET https://conductscience.org/api/papers/v1/301783/cited_by?page=2